Genetic Analysis of Beta-Catenin Function in Human CA
Genetic Analysis of Beta-Catenin Function in Human CA
批准号:
7154043
负责人:
TODD A WALDMAN
金额:
$26.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-03-12 至 2008-12-31
关键词:
APC geneAddressAffectAgarAllelesAnimal ModelAntibodiesBMP4BindingBinding SitesBiochemicalBiologicalBiological ModelsBiologyBrush BorderCaco-2 CellsCancer cell lineCellsColon CarcinomaConfocal MicroscopyCytoplasmDoctor of PhilosophyDrosophila melanogasterElectrical ResistanceElectron MicroscopyElectrophysiology (science)Enzyme-Linked Immunosorbent AssayEpithelial CellsEventGelshift AnalysisGene ExpressionGene TargetingGenesGeneticGrowthHCT116 CellsHalf-LifeHomologous GeneHouse miceHumanImmunodeficient MouseImmunohistochemistryIn VitroKineticsLeadLightMaintenanceMalignant - descriptorMalignant NeoplasmsMeasurementMeasuresMediatingMicroscopyMutationNorthern BlottingNuclearNumbersOncogenesOncogenicPathogenesisPatternPhenotypePhosphorylation SitePilot ProjectsPoint MutationProtein OverexpressionProteinsRangeRateReporterSamplingScanning Transmission Electron Microscopy ProceduresSignal TransductionStaining methodStainsStructureSubcutaneous InjectionsSystemTCF Transcription FactorTCF7L2 geneTestingThinkingTight JunctionsTissuesTranscription CoactivatorTranscriptional ActivationTumor Cell LineTumorigenicityWestern BlottingXenograft procedureactivating transcription factoranti-cancer therapeuticbeta cateninbone morphogenetic protein 4cancer cellcarcinogenesiscell typecolon cancer cell linegene functiongenetic analysisimmunocytochemistryin vivoinhibitor/antagonistlight microscopymalignant statemonolayermutantpromoterprotein functionresearch studyrestorationsmall moleculethree dimensional structuretranscription factortumortumor xenograftvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Oncogenic activation of g-catenin is common to the pathogenesis of a wide range of human cancers. As is the
case for many cancer-related genes, some of the most valuable studies in 13-catenin biology have been
undertaken in genetically tractable model organisms such as Drosophila melanogaster and Mus musculus. By
exploiting recent technological advances in gene targeting it is now possible to undertake similar studies of
gene function in human cancer cells themselves. To do this, we have created high-efficiency human
promoterless 13-catenin gene-targeting vectors and employed them to create isogenic sets of human cancer
cells that differ only in the presence or absence of their endogenous mutant and/or wild-type fS-catenin genes.
Initial functional studies have shed light on several aspects of the function of 13-catenin in human cancer. In
particular, we have shown that activated 13-catenin is necessary for TCF-mediated transcriptional activation in
human cancer cells. We have also demonstrated that deletion of activated g-catenin causes cancer cells to
form dome-like structures, recapitulating a phenotype seen in differentiating Caco-2 cell monolayers. Pilot
experiments have suggested that oncogenic 13-catenin is not required for the human colon cancer cells to form
xenograft tumors in immunodeficient mice. Also surprisingly, we have detected no discernible differences in
the steady state levels and intracellular localization of wild-type and mutant, activated 13-catenin, as detected
by Western Blot and immunocytochemistry analysis. Finally, we have identified and characterized BMP-4, a
TGF-f3 homolog, as a putative effector of activated 13-catenin signaling in human cancer using Affymetrix
Genechip analysis. We propose to further utilize these isogenic human cancer cell systems to study the
functions of activated 13-catenin in the pathogenesis of human cancer. In particular, we plan to: 1) Determine
the cell biological and pathobiologieal phenotypes of activated 13-catenin in human cancer cells and tissues, 2)
Determine whether oncogenic activation of/3-catenin is required for maintenance of tumorigenicity in human
cancer cells containing multiple genetic hits, 3) Determine the biochemical mechanism(s) of g-catenin
activation in human cancer, and 4) Identify and characterize genes regulated by the activated B-catenin
transcription factor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
-
批准号:8501829
-
项目类别:
-
资助金额:$32.23万
-
财政年份:2013
-
负责人:TODD A WALDMAN
-
依托单位:
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
-
批准号:8819107
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2013
-
负责人:TODD A WALDMAN
-
依托单位:
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
-
批准号:8633441
-
项目类别:
-
资助金额:$31.3万
-
财政年份:2013
-
负责人:TODD A WALDMAN
-
依托单位:
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
-
批准号:9008028
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2013
-
负责人:TODD A WALDMAN
-
依托单位:
Development and Application of Endogenous Epitope Tagging Technology in Human Cel
-
批准号:7777680
-
项目类别:
-
资助金额:$16.69万
-
财政年份:2010
-
负责人:TODD A WALDMAN
-
依托单位:
Development and Application of Endogenous Epitope Tagging Technology in Human Cel
-
批准号:8044714
-
项目类别:
-
资助金额:$19.43万
-
财政年份:2010
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
-
批准号:7417921
-
项目类别:
-
资助金额:$24.07万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
-
批准号:7685028
-
项目类别:
-
资助金额:$6.06万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
-
批准号:7105903
-
项目类别:
-
资助金额:$24.79万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-dependent cell size checkpoint in human cells
-
批准号:8690786
-
项目类别:
-
资助金额:$23.4万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-dependent cell size checkpoint in human cells
-
批准号:8578465
-
项目类别:
-
资助金额:$24.12万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-dependent cell size checkpoint in human cells
-
批准号:8840893
-
项目类别:
-
资助金额:$24.12万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
-
批准号:7795200
-
项目类别:
-
资助金额:$24.07万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
-
批准号:7597077
-
项目类别:
-
资助金额:$18.01万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
-
批准号:7232030
-
项目类别:
-
资助金额:$24.07万
-
财政年份:2006
-
负责人:TODD A WALDMAN
-
依托单位:
Isogenic Cell-Based Screen:Cancer-Targeting Catenin(RMI)
-
批准号:7407180
-
项目类别:
-
资助金额:$3.88万
-
财政年份:2005
-
负责人:TODD A WALDMAN
-
依托单位:
Isogenic Cell-Based Screen:Cancer-Targeting Catenin(RMI)
-
批准号:7022520
-
项目类别:
-
资助金额:$7.76万
-
财政年份:2005
-
负责人:TODD A WALDMAN
-
依托单位:
Cell-Based Screens for Cancer:Targeting PTEN (RMI)
-
批准号:6880221
-
项目类别:
-
资助金额:$7.76万
-
财政年份:2004
-
负责人:TODD A WALDMAN
-
依托单位:
Genetic Analysis of Beta-Catenin Function in Human CA
-
批准号:6830781
-
项目类别:
-
资助金额:$27.49万
-
财政年份:2003
-
负责人:TODD A WALDMAN
-
依托单位:
Genetic Analysis of Beta-Catenin Function in Human CA
-
批准号:6576709
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2003
-
负责人:TODD A WALDMAN
-
依托单位:
海外基金